



## **Neurotech secures Greek medical devices specialist Bonvie Group as distribution partner**

- Bonvie Group to exclusively distribute Mente Autism in Greece and Cyprus
  - First devices to be shipped in May, 2017

**Perth, Australia & Malta – 26 April 2017** – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has secured the Bonvie Group (“Bonvie”) as its marketing and distribution partner for Mente Autism in Greece and Cyprus.

Based in Athens, Bonvie is a distributor for high quality products and innovative technology in the medical market, focusing on products that add value to everyday life as well as advancing health and wellbeing for the user. Additional information located on their website at [www.bonviigroup.com](http://www.bonviigroup.com).

Neurotech expects to ship the first batch of devices in May.

Wolfgang Storf, CEO of Neurotech International said: “Our expansion into new markets continues with the appointment of Bonvie as our distribution partner for Greece and Cyprus. It is an established partner in the region with extensive experience in distributing medical devices and building partnerships with medical professional and entities working in this field and, in particular, with patients on the autism spectrum.”

“As we continue to roll out our plans for the German, Austrian and Swiss region, we are also focusing on other new regions that offers numerous opportunities for growth. There is significant, untapped potential in Greece and related markets, and we believe that Bonvie are the ideal partners to do business with here.”

Spiros Vassilakis, CEO of Bonvie said: “Our mission is to partner with companies that have pioneering technology and innovative products to build a healthier and better future for customers. Partnering with Neurotech is a great opportunity to grow together and to enhance our portfolio. Mente Autism is designed to add value to everyday life and advance health and wellbeing, which is completely in line with our vision as a company.”

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

-ends-

---

### **Neurotech International Ltd**

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)

## **About Neurotech**

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: <http://www.neurotechinternational.com>.

*For more information please contact:*

Matthew Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
Tel: +61 451 896 420